A Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19 Omicron) mRNA Vaccine (Phase 1)
Clinical trial NCT05433194 · UNKNOWN
Trial details
- NCT number
- NCT05433194
- Sponsor
- Suzhou Abogen Biosciences Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-22
- Primary completion
- 2022-09-26
- Enrollment
- 48
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.